Cure8 trial brief
A new oral drug, LMT503, is entering first-in-human testing for people with Crohn's disease and ulcerative colitis. Early-phase trials establish safety and how the body handles a drug—important first steps before any effectiveness data are available.
Clinicians and researchers following IBD drug development; patients interested in experimental oral therapies and those tracking upcoming clinical trials.
This is the clinicaltrials.gov record for a Phase 1, first-in-human randomized, double-blind, placebo-controlled study of oral LMT503 in healthy adults or subjects with inflammatory bowel disease (the registry lists Crohn's disease and ulcerative colitis among the conditions).
The trial includes single ascending dose (SAD) with an integrated food-effect arm and a multiple ascending dose (MAD) part to assess safety, tolerability, and pharmacokinetics. Planned enrollment is 72 and the study is not yet recruiting. The primary outcomes are safety-focused (treatment-emergent adverse events, labs, vitals, ECG, telemetry).
Eligibility criteria and contraceptive guidance are detailed in the registry; typical Phase 1 exclusions (recent study participation, drug/alcohol screens, certain infections) apply. If you are considering participation or are tracking emerging IBD treatments, this is an early-stage safety and PK study rather than evidence of efficacy.
The registry entry summarizes the planned design but does not report results.
This is a Phase 1 trial record (NOT_YET_RECRUITING) focused on safety and pharmacokinetics; it does not provide efficacy data. Eligibility and exclusion criteria are typical for first-in-human studies and limit immediate relevance to most patients. Consult the registry entry or trial contacts for up-to-date recruitment and protocol details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future...
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
